ADVFN Logo ADVFN
시장 데이터
뉴스
도구
시장
팔로우

Hot Features

피드 팔로우

Follow Feed 커뮤니티에서 거래자 및 투자자와 연결하세요.

실시간 옵션 플로우

포괄적인 옵션 데이터를 탐색하고 옵션 흐름으로 고급 필터를 사용하세요.

모니터

터미널 모니터로 주식 및 자산 관심 목록을 구성하고 모니터링하세요.
로그인 Premium Icon프리미엄 Help Menu
S&P 500
5,728.80
0.41%
US Tech 100
19,528.00
0.90%
다우존스 지수
42,052.19
0.69%
Bitcoin
69,666.74
0.27%
Registration Strip Icon for default 무료로 등록하여 실시간 주식 시세, 대화형 차트, 실시간 옵션 플로우 등을 받아보세요.
등록
  1. 홈
  2. 인베스팅
  3. 주식
  4. 미국
  5. NASDAQ

  6. Metagenomi Inc (MGX) 시세

Metagenomi Inc

Metagenomi Inc (MGX)

Mount Gibson Iron Limited
2.11
0.14
(7.11%)
마감 02 11월 5:00AM
15분 지연
2.1485
0.0385
(1.82%)
시간외 거래: 6:21AM
15분 지연

포트폴리오 강화: 실시간 토론 및 실행 가능한 거래 아이디어.

프리미엄

주요 통계 및 세부정보

가격
2.1485
매수가
2.01
매도가
2.14
거래량
130,258
1.97 일간 변동폭 2.16
1.85 52주 범위 12.74
market_cap
80.416M
전일 종가
1.97
개장가
1.97
최근 거래 시간
100
@
2.1485
(formt)
마지막 거래 시간
재정 규모
US$ 266,470
VWAP
2.0457
평균 볼륨(3m)
236,041
발행 주식
37,428,994
배당수익률
-
주가수익률
-1.15
주당순이익(EPS)
-1.82
매출
44.76M
순이익
-68.26M

Metagenomi Inc 정보

At Metageno­mi, we are cre­at­ing poten­tial­ly cura­tive ther­a­peu­tics using our metage­­nomics-pow­ered genome edit­ing toolbox.We believe tools with capa­bil­i­ties that go beyond the cur­rent tech­nol­o­gy land­scape will be required in order to reach the full ther­a­peu­tic poten­tial of geno... At Metageno­mi, we are cre­at­ing poten­tial­ly cura­tive ther­a­peu­tics using our metage­­nomics-pow­ered genome edit­ing toolbox.We believe tools with capa­bil­i­ties that go beyond the cur­rent tech­nol­o­gy land­scape will be required in order to reach the full ther­a­peu­tic poten­tial of genome edit­ing. By har­ness­ing the pow­er of metage­nomics, the study of genomes recov­ered from uncul­ti­vat­ed organ­isms in the nat­ur­al envi­ron­ment, we are dis­cov­er­ing and devel­op­ing a suite of nov­el genome edit­ing tools with the poten­tial to make any desired ther­a­peu­tic gene edit, any­where in the human genome. 더 보기

섹터
Biological Pds,ex Diagnstics
산업
Biological Pds,ex Diagnstics
웹사이트
www.metagenomi.co
본부
Wilmington, Delaware, USA
설립됨
-
Metagenomi Inc is listed in the Biological Pds,ex Diagnstics sector of the 나스닥 with ticker MGX. The last closing price for Metagenomi was US$1.97. Over the last year, Metagenomi shares have traded in a share price range of US$ 1.85 to US$ 12.74.

Metagenomi currently has 37,428,994 shares in issue. The market capitalisation of Metagenomi is US$73.74 million. Metagenomi has a price to earnings ratio (PE ratio) of -1.15.

MGX 최신 뉴스

추가 뉴스

Metagenomi, Inc. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm Before November 25, 2024 to Discuss Your Rights - MGX

Metagenomi, Inc. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm Before November 25, 2024 to Discuss Your Rights - MGX PR Newswire NEW YORK, Oct. 31, 2024 NEW...

31 10월 2024
PR Newswire (US)

Shareholders that lost money on Metagenomi, Inc.(MGX) Urged to Join Class Action - Contact The Gross Law Firm to Learn More

Shareholders that lost money on Metagenomi, Inc.(MGX) Urged to Join Class Action - Contact The Gross Law Firm to Learn More PR Newswire NEW YORK, Oct. 28, 2024 NEW YORK, Oct. 28, 2024...

28 10월 2024
PR Newswire (US)

Metagenomi Presents Novel, Highly Specific and Efficient Adenine Base Editors for Broad Genome Editing at ESGCT

Metagenomi Adenine Base Editors (ABEs) demonstrated over 95% genome targetability Simultaneous ABE triplex editing resulted in over 95% protein knockdown in primary T-cells ABE demonstrated...

24 10월 2024
GlobeNewswire Inc.

Metagenomi, Inc. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm Before November 25, 2024 to Discuss Your Rights - MGX

Metagenomi, Inc. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm Before November 25, 2024 to Discuss Your Rights - MGX PR Newswire NEW YORK, Oct. 17, 2024 NEW...

17 10월 2024
PR Newswire (US)

Metagenomi Presents Compact SMART Editing Platform at AIChE 7th International Conference on CRISPR Technologies

Poster presentation highlights SMART adenine base editors (ABEs)small enough to be packaged into a single adeno-associated virus (AAV) Data demonstrate compact SMART system optimizations allowing...

15 10월 2024
GlobeNewswire Inc.

Shareholders that lost money on Metagenomi, Inc.(MGX) should contact The Gross Law Firm about pending Class Action - MGX

Shareholders that lost money on Metagenomi, Inc.(MGX) should contact The Gross Law Firm about pending Class Action - MGX PR Newswire NEW YORK, Oct. 14, 2024 NEW YORK, Oct. 14, 2024 /PRNewswire/...

14 10월 2024
PR Newswire (US)

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of November 25, 2024 in Metagenomi Lawsuit - MGX

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of November 25, 2024 in Metagenomi Lawsuit - MGX PR Newswire NEW YORK, Oct. 10, 2024 NEW YORK, Oct. 10, 2024 /PRNewswire/...

10 10월 2024
PR Newswire (US)

Shareholders of Metagenomi, Inc. Should Contact The Gross Law Firm Before November 25, 2024 to Discuss Your Rights - MGX

Shareholders of Metagenomi, Inc. Should Contact The Gross Law Firm Before November 25, 2024 to Discuss Your Rights - MGX PR Newswire NEW YORK, Oct. 7, 2024 NEW YORK, Oct. 7, 2024 /PRNewswire/...

07 10월 2024
PR Newswire (US)

Investors who lost money on Metagenomi, Inc.(MGX) should contact The Gross Law Firm about pending Class Action - MGX

Investors who lost money on Metagenomi, Inc.(MGX) should contact The Gross Law Firm about pending Class Action - MGX PR Newswire NEW YORK, Sept. 30, 2024 NEW YORK, Sept. 30, 2024 /PRNewswire/...

30 9월 2024
PR Newswire (US)

Metagenomi to Present at Chardan's 8th Annual Genetic Medicines Conference

EMERYVILLE, Calif., Sept. 19, 2024 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (Nasdaq: MGX), a precision genetic medicines company committed to developing curative therapeutics for patients using its...

20 9월 2024
GlobeNewswire Inc.
기간변동변동 %시가고가저가평균 일일 거래량VWAP
10.14857.42522.171.922824172.01096565CS
40.04852.309523809522.12.171.852662591.97191973CS
12-1.2515-36.80882352943.43.631.852360412.28368703CS
26-4.8715-69.39458689467.028.17471.851526543.13242068CS
52-8.1015-79.039024390210.2512.741.851645075.78619051CS
156-8.1015-79.039024390210.2512.741.851645075.78619051CS
260-8.1015-79.039024390210.2512.741.851645075.78619051CS

이동자

모두 보기
  • 가장 활성
  • % 상승자
  • % 패자
기호가격볼륨
VSTEVast Renewable Ltd
US$ 4.98
(149.00%)
68.46M
INVZWInnoviz Technologies Ltd
US$ 0.096
(96.71%)
22.71k
CDXCChromaDex Corporation
US$ 5.87
(68.19%)
37.58M
ATHAAthira Pharma Inc
US$ 0.606
(41.56%)
236.07M
TILEInterface Inc
US$ 23.24
(33.03%)
2.12M
EPIXESSA Pharma Inc
US$ 1.45
(-72.12%)
33.85M
ELABElevai Labs Inc
US$ 0.0288
(-51.19%)
201.61M
OSTOstin Technology Group Company Ltd
US$ 0.275
(-45.00%)
2.27M
LXRXLexicon Pharmaceuticals Inc
US$ 1.23
(-36.92%)
19.96M
VCIGVCI Global Ltd
US$ 0.0583
(-27.58%)
26.13M
ATHAAthira Pharma Inc
US$ 0.606
(41.56%)
236.07M
SQQQProShares UltraPro Short QQQ
US$ 7.44
(-2.11%)
214.96M
NVDANVIDIA Corporation
US$ 135.40
(1.99%)
206.38M
ELABElevai Labs Inc
US$ 0.0288
(-51.19%)
201.61M
INTCIntel Corporation
US$ 23.20
(7.81%)
171.4M

MGX Discussion

게시물 보기
KIPK KIPK 2 월 전
POS ....You are
👍️0
KIPK KIPK 2 월 전
You are a POS dude....
👍️0
theorysuit theorysuit 2 월 전
Added again here in full size. Data looks fantastic.
👍️0
theorysuit theorysuit 2 월 전
https://finance.yahoo.com/news/metagenomi-announces-preclinical-data-lead-200500503.html?soc_src=social-sh&soc_trk=tw&tsrc=twtr

Efficacy and Durability looks promising here. Lotto sized play here sub $3. I think Stage 1 Pump incoming. A deal to replace MRNA would be nice.
👍️0
theorysuit theorysuit 2 월 전
buying in small chunks under $3.
👍️0
theorysuit theorysuit 3 월 전
i'm buying it up as speculative play on cash value. Will hold a tight stop loss.
👍️0
theorysuit theorysuit 3 월 전
every stock that i look into, you are here :)
👍️0
jondoeuk jondoeuk 6 월 전
The IPO was way too early, and one of the few pillars of its business plan was the partnership. The fact that Moderna walked away means that has collapsed. In the future, IP could be another issue.
👍️0
jondoeuk jondoeuk 6 월 전
Try not to end up being a bag holder for VC's shifting overvalued ''dream companies.''
👍️0
jondoeuk jondoeuk 6 월 전
MRNA walks away from the deal that could have generated up to $3B, handing back full global rights and related technologies.
👍️0
Monksdream Monksdream 9 월 전
Nanalyze discusses gene editing companies
👍️0
Monksdream Monksdream 9 월 전
Preclinical company
👍️0

최근 히스토리

NASDAQ
MGX
Metagenomi
ASX
ABT
Abundant Produce
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

대한민국
회사 소개
사업
Popular
앱 받기
App Store
Google Play

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관

© 2024 ADVFN PLC - 모든 권리 보유